Table 2.
Tivanitivib | Crizotinib | ||||
---|---|---|---|---|---|
p-MET inhibition (IC50) | Growth inhibition (IC50) | p-MET inhibition (IC50) | Growth inhibition (IC50) | ||
MDA-MB-231 | Report (5, 8) | 0.1–0.3 μM | 0.55 μM | 0.011 μM | NA |
Test | > 1 μM | 0.65 μM | 0.01–0.1μM | 2.8 μM | |
HT-29 | Report (5, 8) | 0.1–0.3 μM | 0.49 μM | 0.011 μM | NA |
Test | > 1 μM | 0.54 μM | 0.01–0.1μM | 2.6 μM | |
SW1736 | Test | ≈ 1 μM | 0.11 μM | 0. 1–1μM | 2.5 μM |
TL3 | Test | ≈ 1 μM | 0.33 μM | < 0.1μM | 2.6μM |
Note: IC50 values of p-MET inhibition in our tests were estimated according to the western blotting results. NA: not analyzed.